Leukocytosis—an elevated white blood cell count—is a common laboratory finding encountered across inpatient and ambulatory settings. Accurate ICD-10 coding for leukocytosis drives appropriate claim adjudication, reflects clinical complexity, and supports compliance with payer medical necessity rules. For revenue cycle teams and coders, precise assignment and documentation prevent denials, reduce rework, and ensure the record aligns with clinical intent.
This guide explains what the ICD-10-CM code represents, when to use and when not to use it, closely related codes, billing best practices to improve reimbursement, and documentation elements that reduce audit risk. Practical scenarios and query guidance are included so coders and clinicians can apply the code consistently.
The ICD-10-CM Code for Elevated white blood cell count, unspecified is D72.829.
Leukocytosis refers to a laboratory-documented increase in circulating white blood cells above the laboratory-specific reference range. It is a descriptive, non-specific finding that can signal infection, inflammation, stress response, medication effect, tissue necrosis, or hematologic malignancy. In ICD-10-CM, D72.829 is used when the elevated white blood cell count is documented by the clinician but no specific cell line (for example, neutrophilia or lymphocytosis), underlying cause, or associated disorder is specified in the medical record. D72.829 captures the abnormal laboratory finding as a clinical diagnosis when the provider documents leukocytosis or equivalent terminology without further specificity.
Use D72.829 when a patient presents with symptoms (fever, malaise, localized pain) and laboratory testing demonstrates an elevated white blood cell count, but the clinician documents only “leukocytosis” without assigning a cause or subtype. This supports medical necessity for diagnostic workup and short-interval follow-up.
Use D72.829 for visits focused on reviewing an incidental elevated white blood cell count when the clinician documents the finding and orders or reviews confirmatory testing, but there is no documented diagnosis such as infection or hematologic disorder. It is appropriate when the encounter centers on the lab abnormality itself.
Use D72.829 for low-complexity outpatient encounters where the elevated white blood cell count is the primary clinical issue managed (e.g., provider documents leukocytosis and recommends observation or repeat CBC), and no additional specific diagnosis is documented or treated.
Do not use D72.829 if the clinician documents a specific subtype (for example, neutrophilia, lymphocytosis, eosinophilia) or a specific cause such as bacterial pneumonia, urinary tract infection, or leukemia. Instead, assign the more specific code (for example, D72.821 for neutrophilia when documented) or the primary disease code that explains the leukocytosis (for example, J18.9 for pneumonia).
Do not assign D72.829 as a principal diagnosis if leukocytosis is an incidental lab finding secondary to a clearly documented primary diagnosis (for example, sepsis or malignancy) and the visit focuses on management of the primary condition. In those cases, code the underlying condition as principal and list leukocytosis only if it is separately evaluated or treated.
Do not use D72.829 if the laboratory report and clinician note specify the white blood cell differential (for example, “absolute neutrophil count elevated to X” or “lymphocytosis”) and the clinician documents that specific abnormality. Use the code that matches the documented subtype or the underlying etiology rather than the unspecified code.
| Condition | Code | When It Is Used | When It Is Not Used |
|---|---|---|---|
| Elevated white blood cell count, unspecified | D72.829 | When clinician documents leukocytosis or elevated WBC without specifying cell line or cause; used for isolated lab abnormality or workup visits | Not used when a specific cause, subtype, or underlying disease is documented and treated |
| Neutrophilia | D72.821 | When the clinician documents neutrophilia or an elevated neutrophil count (left shift) and links it to evaluation or management | Not used when only general leukocytosis is documented without specification or when an underlying infection code is primary |
| Lymphocytosis | D72.822 | When the clinician documents elevated lymphocyte count and documents evaluation or monitoring for that finding | Not used when lymphocyte elevation is not specified in documentation or when another diagnosis (e.g., viral infection) is coded as primary |
| Leukemoid reaction | D72.826 | When documentation supports a reactive, markedly elevated white count described as leukemoid reaction and the clinician manages it as such | Not used when the elevation is mild, when leukemia or hematologic malignancy is diagnosed, or when only “leukocytosis” is documented without leukemoid characterization |
Include the exact white blood cell result, the laboratory reference range, and the clinician’s interpretation (e.g., “leukocytosis, WBC elevated at X, likely reactive”). Explicit values support medical necessity and reduce denials for undocumented lab findings.
Document how the elevated white blood cell count influenced management (diagnostic testing ordered, treatment initiated, follow-up arranged). Showing that the abnormality affected care strengthens reimbursement rationale.
If chart documentation lists only “elevated WBC,” send a focused query asking the clinician to specify cell line, suspected cause, or whether the finding is incidental. A clarified diagnosis enables assignment of a more specific code when supported.
If leukocytosis is the reason for the visit and is addressed, it can be coded as a primary or secondary diagnosis appropriately. If an underlying infection or hematologic disorder explains the leukocytosis and is the reason for care, code that condition as the principal diagnosis and include leukocytosis only if separately evaluated.
Leverage CombineHealth.ai’s AI-powered platform and its claim scrubbing and coding validation capabilities to flag unspecified lab abnormalities, recommend queries, and improve first-pass acceptance. Automated validation reduces denials related to inconsistent or incomplete documentation.
Coding for leukocytosis has direct impact on revenue cycle outcomes:
Accurate ICD-10 coding is critical for healthcare revenue cycle performance. CombineHealth.ai's AI-powered platform helps RCM teams ensure coding accuracy, reduce denials, and optimize reimbursement through intelligent denial management and claim validation. CombineHealth.ai's intelligent platform provides automated claim scrubbing and coding validation to catch errors before submission, reducing denials and improving first-pass acceptance rates.
Q1: What is the ICD-10 code for leukocytosis?
The ICD-10-CM code for leukocytosis is D72.829. Use this when the clinician documents an elevated white blood cell count but does not specify a cell-line abnormality or an underlying cause in the medical record.
Q2: When should I use D72.829 vs related codes?
Use D72.829 when documentation is limited to “leukocytosis” or “elevated WBC” without further detail. Use specific codes such as D72.821 (neutrophilia), D72.822 (lymphocytosis), or D72.826 (leukemoid reaction) when the clinician documents those subtypes or when an underlying diagnosis (for example, pneumonia or leukemia) explains the abnormality and is the focus of care.
Q3: What documentation is required when coding for leukocytosis?
Document the exact WBC value and lab reference range, clinician interpretation, signs or symptoms prompting testing, diagnostic or therapeutic actions taken, and whether leukocytosis was addressed during the encounter. If the lab abnormality triggers follow-up testing or treatment, capture those orders and plans in the record.
Q4: What are common denial reasons when coding for leukocytosis?
Denials commonly arise from insufficient documentation of the abnormal value or its clinical relevance, coding leukocytosis instead of a more appropriate primary diagnosis, and lack of evidence that the finding affected management. See our guide on denial management for strategies to reduce these denials.